Aurenar, developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in intensive care unit (ICU) patients, today announced the close of an oversubscribed $5.7 million seed financing round, co-led by the Go Red for Women Venture Fund™, part of American Heart Association Ventures™ - the American Heart Association's venture capital arm - and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. Proceeds from the investment round will fund continued advancement toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).

Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company's transauricular vagus nerve stimulation (taVNS) device targets the body's inflammatory response to improve outcomes, lower total cost of care, and transform critical care management. Beginning with the impacts of stroke, Aurenar's platform is positioned to expand to address multiple high-acuity indications.